Dr. Srivastava’s research has been focused on the following two parvoviruses, the non-pathogenic adeno-associated virus (AAV), and a common human pathogen, the parvovirus B19, and the development of recombinant parvovirus vectors in human gene therapy.
Dr. Hoffman is an Associate Professor and cellular immunologist with a major interest in immune modulation and tolerance induction using adeno-associated virus (AAV) gene therapy. Dr. Hoffman earned his Ph.D. in Immunology from Temple University School of Medicine in 2006. He subsequently performed postdoctoral research in gene therapy at University of Florida.
The primary mission is to merge molecular genetics research and health care by developing new therapeutic strategies involving gene transfer. The idea of gene therapy is a logical and natural progression of the last 20 years of research in medical genetics and molecular biology.
The focus of our research is developing viral vector-based gene replacement strategies for the treatment of inherited ocular disease.
|Arun Srivastava, PhD (Contact PI)||National Institutes of Health, or NIH||Next generation of recombinant AAV serotype vectors for gene therapy|
|Arun Srivastava, PhD||NIH||AAV2 and hepatocellular carcinoma|
|Arun Srivastava, PhD (Contact PI)||NIH||Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors|
|Arun Srivastava, PhD||Kitzman Endowment||Research endowment|
|Arun Srivastava, PhD||aaVective, Inc.||Development of clinical candidate NextGen optimized AAV3B serotype vectors for gene therapy of hemophilia B and hemophilia A|
|Brad Hoffman, PhD||NIH National Institute of Allergy and Infectious Diseases||Restoring immune tolerance in a model of multiple sclerosis|
|Brad Hoffman, PhD (Co-PI)||NIH National Institute of Neurological Disorders and Stroke||Immune modulation and CNS pathology following exogenous alpha synuclein challenge|
|Brad Hoffman, PhD (Co-PI)||NIH National Eye Institute||Engineering AAV for safe and efficient gene delivery to the human retina|
|Brad Hoffman, PhD||Sarepta Therapeutics||Development of mouse models for clinical relevance|
|Brad Hoffman, PhD||Sarepta Therapeutics||Vector engineering and production|
|Brad Hoffman, PhD||Sarepta Therapeutics||Determine synergism of current disease modifying therapies|
|Brad Hoffman, PhD||Sarepta Therapeutics||Treg depletion studies in DTR mice|